Latest Breaking News On - Flow electroporation - Page 5 : vimarsana.com

MaxCyte signs licence deal with Vittoria Biotherapeutics

MaxCyte announced a strategic platform licence agreement with Vittoria Biotherapeutics on Monday, granting Vittoria non-exclusive clinical and commercial rights to use MaxCyte's ‘Flow Electroporation’ technology and ‘ExPERT’ platform.

MaxCyte inks strategic platform license with Lyell Immunopharma

MaxCyte Inc on Thursday said it has signed a strategic platform license with Lyell Immunopharma Inc, a clinical stage T cell reprogramming company. The cell-engineering technology platform based in...

MaxCyte inks platform licensing deal with Lyell

MaxCyte to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., June 01, 2023 -- MaxCyte, Inc., a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well... | June 1, 2023

MaxCyte Signs Strategic Platform License with Walking Fish

Walking Fish to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious...

MaxCyte (MXCT) Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

MaxCyte signs strategic platform license with Walking Fish

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Signs a strategic platform license with Walking Fish Therapeutics Inc, a biotechnology company that is rapidly... | May 4, 2023

IN BRIEF: MaxCyte signs strategic platform license with Walking Fish

Role of NK cells to treat B-Cell Lymphoma

This article describes the role of NK cells in cancer cells surveillance and its role in therapy to treat B-Cell Lymphoma.

CRISPR-Cas9 for large-scale engineering

This article describes the role of genome editing to CRISPR-Cas9 Ribonucleoproteins to engineer extracellular nanoparticles.